These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 29732641)
1. Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries. Zimmermann M; Adamson B; Lam-Hine T; Rennie T; Stergachis A Int J Pharm Pract; 2018 Aug; 26(4):364-368. PubMed ID: 29732641 [TBL] [Abstract][Full Text] [Related]
2. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
3. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization. Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831 [TBL] [Abstract][Full Text] [Related]
4. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981 [TBL] [Abstract][Full Text] [Related]
5. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Morel CM; McGuire A; Mossialos E Health Aff (Millwood); 2011 Aug; 30(8):1545-52. PubMed ID: 21821572 [TBL] [Abstract][Full Text] [Related]
6. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Perdue ML; Bright RA Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430 [TBL] [Abstract][Full Text] [Related]
7. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets. Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800 [TBL] [Abstract][Full Text] [Related]
8. Essential Medicines in a High Income Country: Essential to Whom? Duong M; Moles RJ; Chaar B; Chen TF; PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544 [TBL] [Abstract][Full Text] [Related]
9. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012 [TBL] [Abstract][Full Text] [Related]
10. [Access of developing countries to essential drugs: a process of equity]. Campion MD Bull Acad Natl Med; 2001; 185(7):1255-66; discussion 1266-9. PubMed ID: 11975322 [TBL] [Abstract][Full Text] [Related]
11. New vaccine adoption in lower-middle-income countries. Makinen M; Kaddar M; Molldrem V; Wilson L Health Policy Plan; 2012 May; 27 Suppl 2():ii39-49. PubMed ID: 22513731 [TBL] [Abstract][Full Text] [Related]
12. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Oortwijn W; Mathijssen J; Banta D Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829 [TBL] [Abstract][Full Text] [Related]
13. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
14. The complexity and cost of vaccine manufacturing - An overview. Plotkin S; Robinson JM; Cunningham G; Iqbal R; Larsen S Vaccine; 2017 Jul; 35(33):4064-4071. PubMed ID: 28647170 [TBL] [Abstract][Full Text] [Related]
15. Differential pricing of new pharmaceuticals in lower income European countries. Kaló Z; Annemans L; Garrison LP Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049 [TBL] [Abstract][Full Text] [Related]
17. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study. Tauqeer F; Myhr K; Gopinathan U Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684 [TBL] [Abstract][Full Text] [Related]
18. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]
19. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721 [TBL] [Abstract][Full Text] [Related]
20. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. Malhotra S; Cameron AI; Gotham D; Burrone E; Gardner PJ; Loynachan C; Morin S; Scott CP; Pérez-Casas C PLOS Glob Public Health; 2024; 4(7):e0003418. PubMed ID: 38950021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]